Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Blood

Volumn 123, Issue 5, 2014, Pages 632-639

  Mulligan, George ^a   Lichter, David I ^a   Bacco, Alessandra Di ^a   Blakemore, Stephen J ^a   Berger, Allison ^a   Koenig, Erik ^a   Bernard, Hugues ^a   Trepicchio, William ^a   Li, Bin ^a   Neuwirth, Rachel ^a   Chattopadhyay, Nibedita ^a   Bolen, Joseph B ^a   Dorner, Andrew J ^a   Van De Velde, Helgi ^b   Ricci, Deborah ^c   Jagannath, Sundar ^d   Berenson, James R ^e   Richardson, Paul G ^f   Stadtmauer, Edward A ^g   Orlowski, Robert Z ^h   Lonial, Sagar ⁱ   Anderson, Kenneth C ^f   Sonneveld, Pieter ^j   Miguel, Jeśus F San ^k   Esseltine, Dixie Lee ^a   Schu, Matthew ^a   more..

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Janssen Research and Development   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

^e INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF NAVARRA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BORTEZOMIB; DEXAMETHASONE; DNA; JANUS KINASE 3; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

CANCER RECURRENCE; CHROMOSOME ABERRATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SENSITIVITY; GENE FREQUENCY; GENE MUTATION; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; MYELOMA; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; SOMATIC MUTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE PROTEINS; MULTIPLE MYELOMA; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PYRAZINES; RAS PROTEINS; SURVIVAL ANALYSIS;

EID: 84894041669     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-504340     Document Type: Conference Paper

References (46)

1. Munshi NC, Anderson KC, Bergsagel PL, et al; International Myeloma Workshop Consensus Panel 2. Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011;117(18):4696-4700.
2. Corre J, Avet-Loiseau H. The impact of genomics on the management of myeloma. J Natl Compr Canc Netw. 2011;9(10):1200-1206.
3. Decaux O, Lode L, Magrangeas F, et al; Intergroupe Francophone du Myélome. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2008;26(29): 4798-4805.
4. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284.
5. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5): 2516-2520.
6. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335-348.
7. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467-472.
8. Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2(3):344-358.
9. Irahara N, Baba Y, Nosho K, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010;19(3):157-163.
10. Forbes SA, Bindal N, Bamford S, et al. COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(database issue): D945-D950.
11. Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat. 2001;18(3):212-224.
12. Liu P, Leong T, Quam L, et al. Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996;88(7):2699-2706.
13. Prior IA, Hancock JF. Ras trafficking, localization and compartmentalized signalling. Semin Cell Dev Biol. 2012;23(2):145-153.
14. Johnson L, Greenbaum D, Cichowski K, et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 1997;11(19):2468-2481.
15. Esteban LM, Vicario-Abejón C, Fernández-Salguero P, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol. 2001; 21(5):1444-1452.
16. Potenza N, Vecchione C, Notte A, et al. Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. EMBO Rep. 2005;6(5):432-437.
17. Castellano E, Santos E. Functional specificity of ras isoforms: So similar but so different. Genes Cancer. 2011;2(3):216-231.
18. Sclafani F, Gullo G, Sheahan K, Crown J. BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications. Crit Rev Oncol Hematol. 2013;87(1):55-68.
19. Paulsson K, Horvat A, Strömbeck B, et al. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2008; 47(1):26-33.
20. Agrawal N, Jiao Y, Sausen M, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98(2):E364-E369.
21. Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW, Van Ness B. Activating mutations in the N-and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res. 1997;57(11):2268-2275.
22. Richardson PG, Sonneveld P, Schuster MW, et al; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352(24):2487-2498.
23. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127(2):165-172.
24. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26): 2609-2617.
25. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109(8):3177-3188.
26. Cullinan A, Cantor C. Sequenom, Inc. Pharmacogenomics. 2008;9(9):1211-1215.
27. Ragoussis J, Elvidge GP, Kaur K, Colella S. Matrix-assisted laser desorption/ionisation, timeof-flight mass spectrometry in genomics research. PLoS Genet. 2006;2(7):e100.
28. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE. 2009;4(11):e7887.
29. Bladé J, Samson D, Reece D, et al; Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5): 1115-1123.
30. Kiessling MK, Oberholzer PA, Mondal C, et al. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood. 2011;117(8): 2433-2440.
31. Maeng CH, Lee J, van Hummelen P, et al. High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3- kinase and BRAF mutations. PLoS ONE. 2012;7(8):e41655.
32. Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012; 120(5):1060-1066.
33. Soverini S, Terragna C, Testoni N, et al. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica. 2002; 87(10):1036-1040.
34. Metro G, Chiari R, Duranti S, et al. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer. 2012;78(1):81-86.
35. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012;120(5):1077-1086.
36. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26): 6333-6338.
37. Jagannath S, Richardson PG, Barlogie B, et al; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91(7):929-934.
38. Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3(8):862-869.
39. Chng WJ, Gonzalez-Paz N, Price-Troska T, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008; 22(12):2280-2284.
40. Matozaki S, Nakagawa T, Nakao Y, Fujita T. RAS gene mutations in multiple myeloma and related monoclonal gammopathies. Kobe J Med Sci. 1991;37(1):35-45.
41. Ortega MM, Faria RM, Shitara ES, et al. N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma. Leuk Lymphoma. 2006; 47(2):285-289.
42. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 2008;40(5):600-608.
43. Wang Y, Velho S, Vakiani E, et al. Mutant N-RAS protects colorectal cancer cells from stressinduced apoptosis and contributes to cancer development and progression. Cancer Discov. 2013;3(3):294-307.
44. Linden MA, Kirchhof N, Carlson CS, Van Ness BG. Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia. Exp Hematol. 2012; 40(3):216-227.
45. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood. 2005;105(1): 317-323.
46. Mulligan G, Lichter DI, Di Bacco A, et al. Mutational analysis of tumor samples from patients with relapsed or refractory multiple myeloma (MM) highlights the prevalence of RAS/RAF pathway activation and demonstrates previously unreported mutations in known cancer genes. Blood (ASH Annual Meeting Abstracts). 2011;118(21): Abstract 1377.